The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics.
The top five companies covered are Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson and Merck & Co. Sanofi was the largest competitor in the metabolic disorder drugs market in 2017.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
Metabolic Disorders Drugs Global Market Size
The global metabolic disorder drugs market was valued around $87 billion in 2017. North America was the largest region in the metabolic disorder drugs market in 2017, accounting 53% market share. The USA was the largest country in the market accounting for 34% market share.
Metabolic Disorders Drugs Global Market Trend
Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment. Type 2 diabetes is a noninsulin-dependent diabetes that affects sugar (glucose) metabolism of the patient by either resisting or restricting the effects of insulin. In July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients.
Metabolic Disorders Drugs Global Market Segmentation
The metabolic disorders drugs industry is segmented into Anti-Diabetics Drugs, Anti-Thyroid Drugs and Other (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) Drugs.
Anti-Diabetics Drugs companies produce drugs that can be used to manage diabetes by stabilizing and controlling blood glucose levels in diabetic patients. Some of the major anti-diabetics drugs include insulin, pramlintide (amylin), GLP-1 receptor agonists (such as Byetta and Victoza), and oral hypoglycemics (tablets).
Anti-Thyroid Drugs companies produce drugs that can be used for treatment of an overactive thyroid (hyperthyroidism) caused by Graves disease. These drugs are also called thionamides and some of its major examples include methimazole and propylthiouracil.
Other (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) Drugs companies produce drugs for the treatment of disorders related to parathyroid glands, pituitary glands, and adrenal glands. Some of the major examples of hyperparathyroidism, hypopituitarism, hypoadrenalism drugs include calcimimetics and corticosteroids.